Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Surachat Ngorsuraches & Nabin Poudel. (2021) Incorporating patients’ preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review. Expert Review of Pharmacoeconomics & Outcomes Research 21:2, pages 183-195.
Read now
Read now
Andrew Lloyd, Helen Schofield & Nick Adlard. (2020) Cognitive decline may not be adequately captured in economic evaluations of multiple sclerosis: are new treatments being undervalued?. Current Medical Research and Opinion 36:4, pages 609-611.
Read now
Read now
Kathleen Mary Noon, Stephen Maxwell Montgomery, Nicholas Edward Adlard & Michel Anton Kroes. (2018) When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing–remitting multiple sclerosis. Journal of Medical Economics 21:10, pages 983-992.
Read now
Read now
Stephen M. Montgomery, Jeanette Kusel, Richard Nicholas & Nicholas Adlard. (2017) Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility. Journal of Medical Economics 20:9, pages 962-973.
Read now
Read now
Stephen M. Montgomery, Maciej J. Maruszczak, David Slater, Jeanette Kusel, Richard Nicholas & Nicholas Adlard. (2017) A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK. Journal of Medical Economics 20:5, pages 474-482.
Read now
Read now
Articles from other publishers (13)
Ricardo Ginestal, Carlos Rubio-Terrés, Olga Durán Morán, Darío Rubio-Rodríguez, Heidi De Los Santos, Cristina Ordoñez & Isabel Sánchez-Magro. (2023) Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain. Journal of Comparative Effectiveness Research 12:2.
Crossref
Crossref
Hernan Inojosa, Undine Proschmann, Katja Akgün & Tjalf Ziemssen. (2022) The need for a strategic therapeutic approach: multiple sclerosis in check. Therapeutic Advances in Chronic Disease 13, pages 204062232110630.
Crossref
Crossref
Anggie Wiyani, Lohit Badgujar, Vivek Khurana & Nicholas Adlard. (2021) How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review. Neurology and Therapy 10:2, pages 557-583.
Crossref
Crossref
Katelynn Ondek, Aida Nasirishargh, Jacquelyn R. Dayton, Miriam A. Nuño & Lillian Cruz-Orengo. (2021) Strain and sex differences in somatosensation and sociability during experimental autoimmune encephalomyelitis. Brain, Behavior, & Immunity - Health 14, pages 100262.
Crossref
Crossref
Ingrid E. H. Kremer, Mickael Hiligsmann, Josh Carlson, Marita Zimmermann, Peter J. Jongen, Silvia M. A. A. Evers, Svenja Petersohn, Xavier G. L. V. Pouwels & Nick Bansback. (2020) Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model. Medical Decision Making 40:8, pages 1003-1019.
Crossref
Crossref
Lisa Batcheller & David Baker. (2019) Cost of disease modifying therapies for multiple sclerosis: Is front-loading the answer?. Journal of the Neurological Sciences 404, pages 19-28.
Crossref
Crossref
Le H. HuaCarrie M. HershPeter MortenJeanette KuselFeng LinJulie CaveStefan VargaVivian HerreraJohn J. Ko. (2019) The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis. Journal of Managed Care & Specialty Pharmacy 25:4, pages 490-498.
Crossref
Crossref
Luis Hernandez, Malinda O’Donnell & Maarten Postma. (2018) Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations. PharmacoEconomics 36:10, pages 1223-1252.
Crossref
Crossref
Ricardo Constantino Ginestal López. (2018) Eficiencia de las nuevas opciones terapéuticas para el tratamiento de la esclerosis múltiple; una revisión farmacoeconómica. PharmacoEconomics Spanish Research Articles 15:1-4, pages 3-12.
Crossref
Crossref
Sergio Iannazzo, Ange-Christelle Iliza & Louise Perrault. (2017) Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies. PharmacoEconomics 36:2, pages 189-204.
Crossref
Crossref
GJ Melendez-Torres, Peter Auguste, Xavier Armoiry, Hendramoorthy Maheswaran, Rachel Court, Jason Madan, Alan Kan, Stephanie Lin, Carl Counsell, Jacoby Patterson, Jeremy Rodrigues, Olga Ciccarelli, Hannah Fraser & Aileen Clarke. (2017) Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. Health Technology Assessment 21:52, pages 1-352.
Crossref
Crossref
Philippe Laram?e, Aur?lie Millier, Thor-Henrik Brodtkorb, Nora Rahhali, Olivier Cristeau, Samuel Aball?a, Stephen Montgomery, Sara Steeves, Mondher Toumi & J?rgen Rehm. (2016) A Comparison of Markov and Discrete-Time Microsimulation Approaches: Simulating the Avoidance of Alcohol-Attributable Harmful Events from Reduction of Alcohol Consumption Through Treatment of Alcohol Dependence. Clinical Drug Investigation 36:11, pages 945-956.
Crossref
Crossref
Emma D. Deeks. (2015) Dimethyl Fumarate: A Review in Relapsing-Remitting MS. Drugs 76:2, pages 243-254.
Crossref
Crossref